Navigation Links
Genta Incorporated Announces Third Quarter 2007 Financial Results
Date:11/7/2007

- New Phase 3 trial of Genasense(R) in melanoma opens to global accrual

- Clinical trial opened for G4544 treatment of bone disease

- Named-patient/compassionate-use program ships initial supply

- Appeal filed to review FDA decision on Genasense in CLL - Brief high-dose IV infusions of Genasense well-tolerated in new clinical

trial

BERKELEY HEIGHTS, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) today reported financial results for the third quarter ended September 30, 2007 and provided an update on the significant progress made in its pipeline of clinical development programs.

"The third quarter was noteworthy for a number of key initiatives," commented Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "For Genasense, we initiated patient accrual into our global Phase 3 trial in melanoma, known as AGENDA. We secured FDA allowance of the G4544 oral gallium IND and initiated its first clinical trial. We completed the filing of our NDA appeal to FDA in CLL. We showed that brief high-dose infusions of Genasense were well-tolerated, potentially offering new treatment options and improved convenience for patients. Finally, we recorded the first revenues for Genasense from the named-patient program. These are major accomplishments in ambitious programs that should significantly enhance shareholder value."

AGENDA: A randomized Phase 3 trial of Genasense in advanced melanoma

During the 3rd quarter, the first patients were randomized and treated on the AGENDA trial. This trial seeks to confirm the effectiveness and safety of the Genasense/chemotherapy combination in patients who had the
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., Nov. 25 ERT (Nasdaq: ...ey, the Company,s President and CEO, and Keith Sch...FO, are scheduled to present at the 21st Annual Pi...on December 1, 2009 in New York City, New York. ,... by visiting the Company,s corporate website at h...
(Date:11/25/2009)..., Fla., Nov. 25 For many...pecially the 27 million living with untreated hea..., says audiologist Cindy Beyer. ,, Dr. Beyer, s... of America,s largest hearing care and hearing ai...ss to stress, frustration, and social isolation, "...
(Date:11/25/2009)...China, Nov. 25 /PRNewswire-Asia-FirstCall/ -- Chin...r "the Company") (Nasdaq: CSKI ), a,leading fully...producing,over-the-counter drugs in the People,s R... Company recently passed the Chinese National Inst...ical Products ("ICPBP") examination,for two of its...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3NBCH Calls for Cost Containment and System Transformation in Health Care Reform Legislation 53878 1NBCH Calls for Cost Containment and System Transformation in Health Care Reform Legislation 53878 2NBCH Calls for Cost Containment and System Transformation in Health Care Reform Legislation 53878 3Cooperation Between Faith Based Organizations and UNFPA Critical to Maternal Health Say Groups 53875 1Cooperation Between Faith Based Organizations and UNFPA Critical to Maternal Health Say Groups 53875 2deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results 13422 1deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results 13422 2
...tients, LOUISVILLE, Ky., Sept. 29 Potentia Pharm... developing medicines for the treatment,of age-rel...at the,Company,s leading drug candidate, POT-4, ha... I study. POT-4 is a complement inhibitor, which s...ould otherwise lead to local,inflammation, tissue ...
...o improve healthcare,system in the Democratic Repu...n Global,Initiative recognized BD (Becton, Dickins...dical technology company, for its commitment to th...ne system monitoring and,healthcare worker safety ...search Center in the Democratic Republic of the Co...
Other Medicine Technology:Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4 2Clinton Global Initiative Announces BD's Commitment to Biamba Marie Mutombo Hospital 2Clinton Global Initiative Announces BD's Commitment to Biamba Marie Mutombo Hospital 3
(Date:11/27/2009)... Walking and cycling plus low-emission vehicles ma... , FRIDAY, Nov. 27 (HealthDay News) -- En...d of using cars would offer much greater public he...vehicles, U.K. researchers have found. , The st...of alternative urban land transport scenarios for ...
(Date:11/27/2009)..., Voyant Health™ an...Michigan) has licensed its TraumaCad Enterprise or...end workflow solution. , ...announced today that Spectrum Health (Grand Rapids...orthopedic templating solution and its TraumaCad E...
(Date:11/27/2009)..., Three new interactive a... Williams & Wilkins expand health sciences lea... Durham, NC (Vocus) November...ams & Wilkins (LWW), a division of Wolters Klu...ree new anatomy education apps on the App Store. C...
(Date:11/26/2009)..., In the next 25 years, the number of Americans l... from 23.7 million in 2009 to 44.1 million in 2034...almost triple, rising from $113 billion to $336 bi...obesity, researchers based at the University of Ch...re . , The number of those with diabetes covered...
(Date:11/26/2009)... Fans get a bigger thrill when on an emotional rol...v. 26 (HealthDay News) -- Call it the fear factor ...ggests that spectators -- especially those who roo...faction if it,s a closely contested match and vict...even despair. , Chew on that this Thanksgiving ...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3
...ies for treating chronic pain , FRIDAY, Nov. 2 (H...xynitrite, a potent oxidant that,s formed when pat...f tolerance to the pain-relieving effects of the n...issue of the Journal of Clinical Investigation , ...
...ember 7, 2007, WALTHAM, Mass., Nov. 2 Interleuki... it will release its third quarter,financial resul...s. The,Company,s management will host the conferen...s the live call on November 7, 2007 at 4:30 PM EST...
...als, Inc. (NYSE: BRL ) today confirmed that its s...a challenge of the patents listed by,Novartis Phar...alin(R) LA,(methylphenidate hydrochloride) extende...eneric Ritalin LA product with the U.S.,Food & Dru...
... Patients Requiring,Dialysis; More Than 700 North...SEGUNDO, Calif. Nov. 2 DaVita, Inc., one,of the n...services in the,United States, announced today its...lly for kidney disease patients,by nearly 50 perce...
...sing events to find the cure, CLEVELAND, Nov. 2 ...ed November as Tay-Sachs Awareness Month,and encou...ce of genetic,testing and the need for research to...ish Americans. One in every 250 people,is a carrie...
...Dental Clinic Services, HARRISBURG, Pa., Nov. 2 ... announced the award of more than $1.1,million in ...access to,primary medical and dental care in Penns...erships to create or expand,primary care medical a...
Other Medicine News:Health News:Blocking Potent Oxidant Could Prevent Morphine Tolerance 2Health News:Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7 2Health News:Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7 3Health News:Barr Confirms Patent Challenge of Ritalin(R) LA 2Health News:Barr Confirms Patent Challenge of Ritalin(R) LA 3Health News:DaVita to Open First Independent Dialysis Clinic in Fargo-Moorhead 2Health News:Governor Strickland Declares November Tay-Sachs Awareness Month 2Health News:Governor Strickland Declares November Tay-Sachs Awareness Month 3Health News:PA Health Department Awards Community Primary Care Challenge Grants 2
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
Medicine Products: